{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:23:58Z","timestamp":1787509438024,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022IP0062-1"],"award-info":[{"award-number":["2022IP0062-1"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["2018M3A9D3079500"],"award-info":[{"award-number":["2018M3A9D3079500"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jbspin.2022.105510","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T20:05:53Z","timestamp":1670961953000},"page":"105510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical significance of tocilizumab-related neutropenia in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"90","author":[{"given":"Young-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Keun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2022.105510_bib0225","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar1969","article-title":"Interleukin-6: a new therapeutic target","volume":"8","author":"Smolen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105510_bib0230","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jbspin.2022.105510_bib0235","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105510_bib0240","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105510_bib0245","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","article-title":"Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo","volume":"53","author":"Wright","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2022.105510_bib0250","doi-asserted-by":"crossref","first-page":"H879","DOI":"10.1152\/ajpheart.00185.2002","article-title":"The effect of interleukin-6 on L-selectin levels on polymorphonuclear leukocytes","volume":"283","author":"Suwa","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jbspin.2022.105510_bib0255","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105510_bib0260","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2022.105510_bib0265","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105510_bib0270","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105510_bib0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105510_bib0280","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105510_bib0285","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105510_bib0290","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kex238","article-title":"Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE","volume":"56","author":"Morel","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105510_bib0295","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105510_bib0300","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","article-title":"Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105510_bib0305","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.140665","article-title":"Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study","volume":"42","author":"Ogata","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105510_bib0310","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2022.105510_bib0315","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s10067-016-3357-z","article-title":"Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Zamora-Legoff","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105510_bib0320","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.jbspin.2022.105510_bib0325","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105510_bib0330","unstructured":"National cancer institute. Cancer therapy EvaluationProgram: common terminology criteria for AdverseEvents V3.0 (CTCAE), http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf; 2006.[accessed Jul 21.2022]."},{"key":"10.1016\/j.jbspin.2022.105510_bib0335","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/acr.20037","article-title":"Neutropenia in patients receiving anti-tumor necrosis factor therapy","volume":"62","author":"Hastings","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2022.105510_bib0340","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/pgmj.76.902.787","article-title":"Safety of low dose methotrexate in elderly patients with rheumatoid arthritis","volume":"76","author":"Hirshberg","year":"2000","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jbspin.2022.105510_bib0345","doi-asserted-by":"crossref","first-page":"e0154744","DOI":"10.1371\/journal.pone.0154744","article-title":"Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases","volume":"11","author":"Mori","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2022.105510_bib0350","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cpt.805","article-title":"Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus","volume":"103","author":"Wadelius","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2022.105510_bib0355","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/ard.45.9.761","article-title":"Neutropenia in patients with inflammatory arthritis treated with sulphasalazine","volume":"45","author":"Farr","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105510_bib0360","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbspin.2022.105510_bib0365","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood.V86.8.3181.3181","article-title":"Glucocorticoids inhibit apoptosis of human neutrophils","volume":"86","author":"Liles","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2022.105510_bib0370","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.4049\/jimmunol.166.10.6294","article-title":"A Potential role for Annexin 1 as a physiologic mediator of glucocorticoid-induced L-selectin shedding from myeloid cells","volume":"166","author":"Strausbaugh","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2022.105510_bib0375","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","article-title":"Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo","volume":"53","author":"Wright","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105510_bib0380","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/eci.12799","article-title":"Effects of tocilizumab on neutrophil function and kinetics","volume":"47","author":"Lok","year":"2017","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.jbspin.2022.105510_bib0385","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105510_bib0390","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2019.00238","article-title":"Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment","volume":"6","author":"Fragoulis","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jbspin.2022.105510_bib0395","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105510_bib0400","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11926-010-0130-1","article-title":"Rheumatoid vasculitis: vanishing menace or target for new treatments?","volume":"12","author":"Bartels","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2022.105510_bib0405","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/14397595.2013.874748","article-title":"Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis","volume":"25","author":"Iijima","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105510_bib0410","first-page":"1657","article-title":"The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age","volume":"40","author":"Specker","year":"2022","journal-title":"Clin Experimental Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105510_bib0415","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105510_bib0420","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.rmed.2012.07.006","article-title":"Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis","volume":"106","author":"Mori","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.jbspin.2022.105510_bib0425","article-title":"C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab","volume":"2013","author":"Bari","year":"2013","journal-title":"Case Rep"},{"key":"10.1016\/j.jbspin.2022.105510_bib0430","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-022-02887-7","article-title":"Calprotectin (S100A8\/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy","volume":"24","author":"Gernert","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105510_bib0435","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","article-title":"Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)","volume":"75","author":"Burmester","year":"2016","journal-title":"Annals of the Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105510_bib0440","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.3346\/jkms.2022.37.e138","article-title":"Predictive factors for rheumatoid arthritis flare after switching from intravenous to subcutaneous formulation of tocilizumab in real-world practice","volume":"37","author":"Ahn","year":"2022","journal-title":"J Korean Med Sci"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:30:08Z","timestamp":1761150608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X22001701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1297319X22001701"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105510","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical significance of tocilizumab-related neutropenia in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105510"}}